Dementia News and Research

Latest Dementia News and Research

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Sun Pharma announced launch of generic Exelon, rivastigmine tartrate capsules for the US market. Earlier, USFDA had granted final approval for the Company's ANDA to market these products.

2 Jul 2010

Genes can predict longevity with 77% accuracy: Study

In an analysis of genes of more than 1,000 centenarians, American researchers have come to the conclusion that genes play a large role in completing a century in life. The research team studied 1,055 Caucasians born between 1890 and 1910 and compared them with 1,267 people born later. They claim that there are signatures in the genetic makeup of these people that have a possible link with their longevity.

2 Jul 2010

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Caraco Pharmaceutical Laboratories, Ltd. has started shipping rivastigmine tartrate capsules. These products, approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA), are therapeutically equivalent to Exelon® capsules from Novartis.

2 Jul 2010

Watson commences shipment of generic Exelon

Watson Pharmaceuticals, Inc. announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is used to treat dementia in people with Alzheimer's disease.

1 Jul 2010

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Some of the first analyses on the impact of Medicare Part D, as well as new insights on drug adherence patterns by chronic disease patients, will be presented today and tomorrow at the 2010 Academy/Health Annual Meeting by several University of Maryland, Baltimore teams of pharmaceutical health services researchers.

1 Jul 2010

Best Friends Bill of Rights outlines 12 rules to help caregivers enhance lives of patients with Alzheimer's disease

Caring for someone with Alzheimer's or dementia can be a daunting task, even for the most experienced of professionals working with seniors daily in assisted living and memory care. Now there is help and guidance from the experts at Best Friends Approach Virginia Bell and David Troxel. The Best Friends Bill of Rights outlines 12 rules that when adapted, can make a world of difference in the quality of daily life to the one suffering as well as those acting in the role of caregiver.

1 Jul 2010

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Gold Standard Diagnostics, Inc. a leading supplier of products and services to the medical diagnostic industry today announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the U.S. Market. Axis-Shield owns a number of patents in the areas of cardiovascular and neurodegenerative diseases, rheumatoid arthritis, diabetes and more recently, sepsis. GSD will initially focus on distribution of Homocysteine, but also gains access to distribute Axis-Shield's other key products such as Anti-CCP.

1 Jul 2010

Physically-active women have lower risk of dementia in later life

Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.

30 Jun 2010

Study evaluates potential risks and benefits of moderate alcohol consumption

A discussion by renowned epidemiologist Kenneth Mukamal has recently been published in the Journal of the American Medical Association, JAMA. It provides a discussion in response to a theoretical question, - if you are a 42 year old male, should you drink alcohol ( in moderation) for your health?

30 Jun 2010

New tool could aid in diagnosing Alzheimer's, track disease progression

A trial of a novel radioactive compound readily and safely distinguished the brains of Alzheimer's disease patients from healthy volunteers on brain scans and opens the doors to making such imaging available beyond facilities that can manufacture their own radioactive compounds.

29 Jun 2010

Older adults spend more time watching TV, but find it less enjoyable

We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.

29 Jun 2010

ARS study finds link between vitamin D and cognitive function

At a time when consumer interest in health-enhancing foods is high, Agricultural Research Service (ARS)-funded scientists have contributed to a limited but growing body of evidence of a link between vitamin D and cognitive function.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

For the very first time, a medicine has been shown to protect against the development of Alzheimer's disease. French scientists were able to demonstrate that taking 240 mg of Ginkgo extract EGb 761 per day regularly over a period of at least 4 years can cut the risk of developing Alzheimer's disease by nearly 50%.

23 Jun 2010

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

Ipsen today announced top line results of GuidAge®, the longest (5 years) and largest (2,854 subjects) European study in the prevention of Alzheimer's Dementia (AD). This trial was conducted according to the most stringent international standards. The aim of this study was to assess the efficacy of a 5-year treatment with EGb 761® in the prevention of Alzheimer's Dementia in a population of elderly aged 70 or more, with memory complaint spontaneously expressed to their family physician and who lived at home at the inclusion in the study.

22 Jun 2010

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Forest Laboratories, Inc. and Merz Pharmaceuticals GmbH announced today that NAMENDA XR(TM) (memantine hydrochloride) was approved by the U.S. Food and Drug Administration for the treatment of moderate to severe dementia of the Alzheimer's type. NAMENDA XR is a 28 mg once-daily extended-release formulation of NAMENDA.

22 Jun 2010

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

In diverse neurodegenerative diseases ranging from Parkinson's to Alzheimer's, researchers have long noted accumulations of a little-understood neuronal protein called α-synuclein. Pathological and genetic evidence strongly suggested that excessive α-synuclein played a role in the evolution of these diseases, but it was unclear how too much α-synuclein culminated in synaptic damage and neurodegeneration.

17 Jun 2010

Alzheimer's disease may damage brain

Alzheimer's disease has long been studied primarily as a disease of neurons. But researchers have now shown how the disease may be damaging the brain by choking off blood flow. In experiments published June 10 in Neuron, scientists at Rockefeller University reveal that amyloid-β, which builds up around brain cells in Alzheimer's patients, interacts with a common blood clotting agent to increase clotting in the arteries that feed the brain.

17 Jun 2010

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

The Institute for Systems Biology (ISB) of Seattle, WA, is collaborating with the Gladstone Institute of Neurological Disease (GIND) and its Taube-Koret Center for Huntington's Disease Research to use whole-genome sequencing to identify genes and novel drug targets related to the onset and progression of Huntington's disease (HD). The research team, led by GIND associate director and senior investigator Steven Finkbeiner, MD, PhD, will also use induced pluripotent stem (iPS) cells from patients with HD to screen for drugs that might delay, prevent, or even reverse this devastating condition.

16 Jun 2010

Dementia News and Research

Latest Dementia News and Research

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Genes can predict longevity with 77% accuracy: Study

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Watson commences shipment of generic Exelon

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Best Friends Bill of Rights outlines 12 rules to help caregivers enhance lives of patients with Alzheimer's disease

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Physically-active women have lower risk of dementia in later life

Study evaluates potential risks and benefits of moderate alcohol consumption

New tool could aid in diagnosing Alzheimer's, track disease progression

Older adults spend more time watching TV, but find it less enjoyable

ARS study finds link between vitamin D and cognitive function

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

Alzheimer's disease may damage brain

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dementia News and Research

Latest Dementia News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in